PRCT

PRCT

Procept Biorobotics Corp

Net -14.84%top 1%Rev 9.51%top 1%Revenue grew 100% of years1Y
Hold

Procept BioRobotics develops and sells the AquaBeam and HYDROS robotic systems, which provide image-guided, minimally invasive surgical solutions for urology, focusing on treating benign prostatic hyperplasia and related urinary tract symptoms.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$551today

Score Overview

1 Year
Scoreโ€”
Net Growth-14.84%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth9.51%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-83.37%
Net Trend20%
Net Income Consistency
Rev Growth9x
Rev TrendEvery year
Revenue Consistency

See the full market ranking โ†’

Procept Biorobotics Corp fundamental performance

Across Procept Biorobotics Corp's full reported history, from 2021 to 2025, revenue grew from $ 34M to $ 308M and net income went from -$ 59M to -$ 95M. Revenue increased in 100% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 21.25โ€”
1 Year2025-08-12
$ 38.60-44.95%
All Time2021-09-15
$ 41.94-49.33%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 337M-$ 109M$ 227M
2025$ 308M-$ 95M$ 286M
2024$ 224M-$ 91M$ 333M
2023$ 136M-$ 105M$ 257M
2022$ 75M-$ 87M$ 222M
IPO2021$ 34M-$ 59M$ 304M

Explore beyond PRCT

You're looking at Procept Biorobotics Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies